Jefferies analyst, Maury Raycroft, reiterated his Buy rating on shares of Intellia Therapeutics (NASDAQ: NTLA) after hosting investors for an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE